Zachary T. Bloomgarden, MD, MACE: In individuals with liver disease, one has to be cognizant that there is a small but definite potential for abnormalities of liver chemistries with statins. By and large, individuals with chronic liver disease do tolerate statins well, although they (patients) require careful observation of liver chemistries.
In the setting of acute hepatitis, the better part of valor would be to avoid statin therapy since the statins really should be seen as long-term drugs, not drugs that must be given every moment of an individual’s lifetime.
Liver disease should be a consideration, but the minor abnormalities of liver chemistry, which occur with statin therapy, are currently seen as not representing serious clinical conditions.
With renal disease, there is a bit of evidence that very high doses of statins, particularly rosuvastatin, may have adverse effects on renal function. So, as a consequence, one needs to use these drugs with a bit of greater caution in individuals with renal insufficiency. There’s also some evidence that individuals with very advanced kidney disease at the level of dialysis or just predialysis may have attenuation of the benefit of statins in reducing cardiovascular end points. So this is a group to bear in mind, and certainly we do have to be careful in individuals with any severe chronic kidney disease (CKD) when administering statins.
But they [statins] are effective agents and we have to remember that individuals with CKD, especially those with stage 3 and higher CKD, rarely die of progression to end-stage renal disease. Rather, in those individuals, CKD is essentially a cardiovascular risk marker. As such, the prevention of cardiovascular disease, which we know statins can offer, is of much greater importance than the potential interaction. So monitor, monitor, monitor. Be careful in administering these drugs, but individuals with CKD can [absolutely] receive statins when used appropriately.
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More